Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 358

1.

Association of Giant Cell Arteritis With Race.

Gruener AM, Poostchi A, Carey AR, Eberhart CG, Henderson AD, Chang JR, McCulley TJ.

JAMA Ophthalmol. 2019 Aug 8. doi: 10.1001/jamaophthalmol.2019.2919. [Epub ahead of print]

PMID:
31393529
2.

Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma.

Hanaford AR, Alt J, Rais R, Wang SZ, Kaur H, Thorek DLJ, Eberhart CG, Slusher BS, Martin AM, Raabe EH.

Transl Oncol. 2019 Jul 21;12(10):1314-1322. doi: 10.1016/j.tranon.2019.05.013. [Epub ahead of print]

3.

Unbiased metabolic profiling predicts sensitivity of high MYC-expressing atypical teratoid/rhabdoid tumors to glutamine inhibition with 6-diazo-5-oxo-L-norleucine.

Wang SZ, Poore B, Alt J, Price A, Allen SJ, Hanaford AR, Kaur H, Orr BA, Slusher BS, Eberhart CG, Raabe EH, Rubens JA.

Clin Cancer Res. 2019 Jul 12. pii: clincanres.0189.2019. doi: 10.1158/1078-0432.CCR-19-0189. [Epub ahead of print]

PMID:
31300448
4.

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN.

Neuro Oncol. 2019 Jul 4. pii: noz119. doi: 10.1093/neuonc/noz119. [Epub ahead of print]

PMID:
31276167
5.

ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation.

Martínez H, Nagurney M, Wang ZX, Eberhart CG, Heaphy CM, Curtis MT, Rodriguez FJ.

J Neuropathol Exp Neurol. 2019 May 27. pii: nlz050. doi: 10.1093/jnen/nlz050. [Epub ahead of print]

PMID:
31225581
6.

A fox with many faces: FOXR2 and embryonal brain tumors.

Eberhart CG.

Neuro Oncol. 2019 May 31. pii: noz102. doi: 10.1093/neuonc/noz102. [Epub ahead of print] No abstract available.

PMID:
31149715
7.

Periocular Histiocytoid Carcinoma: Potential Diagnostic Challenges.

Yates JR, Mines MJ, Subramanian PS, Rivera-Michlig R, Cummings TJ, Eberhart CG.

Ocul Oncol Pathol. 2019 Feb;5(2):94-101. doi: 10.1159/000490250. Epub 2018 Jul 5.

8.

Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma.

Wang J, Merino DM, Light N, Murphy BL, Wang YD, Guo X, Hodges AP, Chau LQ, Liu KW, Dhall G, Asgharzadeh S, Kiehna EN, Shirey RJ, Janda KD, Taylor MD, Malkin D, Ellison DW, VandenBerg SR, Eberhart CG, Sears RC, Roussel MF, Gilbertson RJ, Wechsler-Reya RJ.

Cancer Res. 2019 May 1;79(9):2208-2219. doi: 10.1158/0008-5472.CAN-18-2565. Epub 2019 Mar 18.

PMID:
30885981
9.

Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.

Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M.

J Neurooncol. 2019 May;143(1):87-93. doi: 10.1007/s11060-019-03134-x. Epub 2019 Mar 12.

10.

MYC Drives Group 3 Medulloblastoma through Transformation of Sox2+ Astrocyte Progenitor Cells.

Tao R, Murad N, Xu Z, Zhang P, Okonechnikov K, Kool M, Rivero-Hinojosa S, Lazarski C, Zheng P, Liu Y, Eberhart CG, Rood BR, Packer R, Pei Y.

Cancer Res. 2019 Apr 15;79(8):1967-1980. doi: 10.1158/0008-5472.CAN-18-1787. Epub 2019 Mar 12.

PMID:
30862721
11.

Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.

Schlein LJ, Fadl-Alla B, Pondenis HC, Lezmi S, Eberhart CG, LeBlanc AK, Dickinson PJ, Hergenrother PJ, Fan TM.

Front Oncol. 2019 Feb 25;9:96. doi: 10.3389/fonc.2019.00096. eCollection 2019.

12.

Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization.

Wang B, Tang Y, Oh Y, Lamb NW, Xia S, Ding Z, Chen B, Suarez MJ, Meng T, Kulkarni V, Eberhart CG, Ensign LM, Stark WJ, Hanes J, Xu Q.

Nanomedicine. 2019 Apr;17:119-123. doi: 10.1016/j.nano.2019.01.001. Epub 2019 Jan 21.

PMID:
30677499
13.

Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors.

Beckmann PJ, Larson JD, Larsson AT, Ostergaard JP, Wagner S, Rahrmann EP, Shamsan GA, Otto GM, Williams RL, Wang J, Lee C, Tschida BR, Das P, Dubuc AM, Moriarity BS, Picard D, Wu X, Rodriguez FJ, Rosemarie Q, Krebs RD, Molan AM, Demer AM, Frees MM, Rizzardi AE, Schmechel SC, Eberhart CG, Jenkins RB, Wechsler-Reya RJ, Odde DJ, Huang A, Taylor MD, Sarver AL, Largaespada DA.

Cancer Res. 2019 Mar 1;79(5):905-917. doi: 10.1158/0008-5472.CAN-18-1261. Epub 2019 Jan 23.

PMID:
30674530
14.

Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.

Luo L, Yang J, Oh Y, Hartsock MJ, Xia S, Kim YC, Ding Z, Meng T, Eberhart CG, Ensign LM, Thorne JE, Stark WJ, Duh EJ, Xu Q, Hanes J.

J Control Release. 2019 Feb 28;296:68-80. doi: 10.1016/j.jconrel.2019.01.018. Epub 2019 Jan 17.

PMID:
30660629
15.

Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high-MYC medulloblastoma.

Natsumeda M, Liu Y, Nakata S, Miyahara H, Hanaford A, Ahsan S, Stearns D, Skuli N, Kahlert UD, Raabe EH, Rodriguez FJ, Eberhart CG.

Neuropathology. 2019 Apr;39(2):71-77. doi: 10.1111/neup.12534. Epub 2019 Jan 10.

PMID:
30632221
16.

Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways.

Halani SH, Yousefi S, Velazquez Vega J, Rossi MR, Zhao Z, Amrollahi F, Holder CA, Baxter-Stoltzfus A, Eschbacher J, Griffith B, Olson JJ, Jiang T, Yates JR, Eberhart CG, Poisson LM, Cooper LAD, Brat DJ.

NPJ Precis Oncol. 2018 Nov 6;2:24. doi: 10.1038/s41698-018-0067-9. eCollection 2018.

17.

ACVR1C/SMAD2 signaling promotes invasion and growth in retinoblastoma.

Asnaghi L, White DT, Key N, Choi J, Mahale A, Alkatan H, Edward DP, Elkhamary SM, Al-Mesfer S, Maktabi A, Hurtado CG, Lee GY, Carcaboso AM, Mumm JS, Safieh LA, Eberhart CG.

Oncogene. 2019 Mar;38(12):2056-2075. doi: 10.1038/s41388-018-0543-2. Epub 2018 Nov 6.

18.

Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy.

Jiang S, Eberhart CG, Lim M, Heo HY, Zhang Y, Blair L, Wen Z, Holdhoff M, Lin D, Huang P, Qin H, Quinones-Hinojosa A, Weingart JD, Barker PB, Pomper MG, Laterra J, van Zijl PCM, Blakeley JO, Zhou J.

Clin Cancer Res. 2019 Jan 15;25(2):552-561. doi: 10.1158/1078-0432.CCR-18-1233. Epub 2018 Oct 26.

PMID:
30366937
19.

Pituitary Adenoma Apoplexy of the Orbit, Diagnosis, and Management With Presurgical Embolization.

Hodgson NM, Campbell AA, Chang JR, Vizcaino A, Eberhart C, Pearl MS, McCulley TJ.

Ophthalmic Plast Reconstr Surg. 2018 Nov/Dec;34(6):e196-e197. doi: 10.1097/IOP.0000000000001241.

PMID:
30320714
20.

Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33.

Tantravedi S, Vesuna F, Winnard PT Jr, Martin A, Lim M, Eberhart CG, Berlinicke C, Raabe E, van Diest PJ, Raman V.

Transl Oncol. 2019 Jan;12(1):96-105. doi: 10.1016/j.tranon.2018.09.002. Epub 2018 Oct 3.

21.

Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.

Poore B, Yuan M, Arnold A, Price A, Alt J, Rubens JA, Slusher BS, Eberhart CG, Raabe EH.

Neuro Oncol. 2019 Feb 14;21(2):252-263. doi: 10.1093/neuonc/noy150.

PMID:
30239952
22.

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.

Brosnan-Cashman JA, Yuan M, Graham MK, Rizzo AJ, Myers KM, Davis C, Zhang R, Esopi DM, Raabe EH, Eberhart CG, Heaphy CM, Meeker AK.

PLoS One. 2018 Sep 18;13(9):e0204159. doi: 10.1371/journal.pone.0204159. eCollection 2018.

23.

MicroRNA (miR) 125b regulates cell growth and invasion in pediatric low grade glioma.

Yuan M, Da Silva ACAL, Arnold A, Okeke L, Ames H, Correa-Cerro LS, Vizcaino MA, Ho CY, Eberhart CG, Rodriguez FJ.

Sci Rep. 2018 Aug 21;8(1):12506. doi: 10.1038/s41598-018-30942-4.

24.

Pathologic study of early manifestations of polypoidal choroidal vasculopathy and pathogenesis of choroidal neo-vascularization.

Tso MOM, Suarez MJ, Eberhart CG.

Am J Ophthalmol Case Rep. 2017 Oct 4;11:176-180. doi: 10.1016/j.ajoc.2017.10.012. eCollection 2018 Sep.

25.

Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma.

Snuderl M, Kannan K, Pfaff E, Wang S, Stafford JM, Serrano J, Heguy A, Ray K, Faustin A, Aminova O, Dolgalev I, Stapleton SL, Zagzag D, Chiriboga L, Gardner SL, Wisoff JH, Golfinos JG, Capper D, Hovestadt V, Rosenblum MK, Placantonakis DG, LeBoeuf SE, Papagiannakopoulos TY, Chavez L, Ahsan S, Eberhart CG, Pfister SM, Jones DTW, Karajannis MA.

Nat Commun. 2018 Jul 20;9(1):2868. doi: 10.1038/s41467-018-05029-3.

26.

Heterogeneity within the PF-EPN-B ependymoma subgroup.

Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, McLendon RE, Lipp ES, Gururangan S, Grossbach A, French P, Kros JM, van Veelen MC, Rao AAN, Giannini C, Leary S, Jung S, Faria CC, Mora J, Schüller U, Alonso MM, Chan JA, Klekner A, Chambless LB, Hwang EI, Massimino M, Eberhart CG, Karajannis MA, Lu B, Liau LM, Zollo M, Ferrucci V, Carlotti C, Tirapelli DPC, Tabori U, Bouffet E, Ryzhova M, Ellison DW, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Pfister SM, Taylor MD, Aldape K, Pajtler KW, Kool M, Ramaswamy V.

Acta Neuropathol. 2018 Aug;136(2):227-237. doi: 10.1007/s00401-018-1888-x. Epub 2018 Jul 17.

27.

Development and Optimization of Metagenomic Next-Generation Sequencing Methods for Cerebrospinal Fluid Diagnostics.

Simner PJ, Miller HB, Breitwieser FP, Pinilla Monsalve G, Pardo CA, Salzberg SL, Sears CL, Thomas DL, Eberhart CG, Carroll KC.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00472-18. doi: 10.1128/JCM.00472-18. Print 2018 Sep.

28.

Endocrine mucin-producing sweat gland carcinoma: A study of 11 cases with molecular analysis.

Qin H, Moore RF, Ho CY, Eshleman J, Eberhart CG, Cuda J.

J Cutan Pathol. 2018 Jun 25. doi: 10.1111/cup.13308. [Epub ahead of print]

PMID:
29943394
29.

Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival.

Lopez-Bertoni H, Kozielski KL, Rui Y, Lal B, Vaughan H, Wilson DR, Mihelson N, Eberhart CG, Laterra J, Green JJ.

Nano Lett. 2018 Jul 11;18(7):4086-4094. doi: 10.1021/acs.nanolett.8b00390. Epub 2018 Jun 28.

30.

Association of Macular and Peripheral Retinal Macro-Pseudocysts With Chronic Retinal Detachment.

Liu TYA, Vizcaino MA, Eberhart CG, Sachdeva MM.

JAMA Ophthalmol. 2018 Aug 1;136(8):956-958. doi: 10.1001/jamaophthalmol.2018.2189. No abstract available.

31.

Ocular Histopathology and Immunohistochemical Analysis in the Oldest Known Individual with Autosomal Dominant Vitreoretinochoroidopathy.

Goldberg MF, McLeod S, Tso M, Packo K, Edwards M, Bhutto IA, Baldeosingh R, Eberhart C, Weber BHF, Lutty GA.

Ophthalmol Retina. 2018 Apr;2(4):360-378. doi: 10.1016/j.oret.2017.08.001.

32.

Primary mesenchymal chondrosarcoma of the orbit: Histopathological report of 3 pediatric cases.

Alkatan HM, Eberhart CG, Alshomar KM, Elkhamary SM, Maktabi AMY.

Saudi J Ophthalmol. 2018 Jan-Mar;32(1):69-74. doi: 10.1016/j.sjopt.2018.02.016. Epub 2018 Mar 8.

33.

Orbital progressive transformation of germinal centers as part of the spectrum of IgG4-related ophthalmic disease: Clinicopathologic features of three cases.

Vizcaino MA, Joseph SS, Eberhart CG.

Saudi J Ophthalmol. 2018 Jan-Mar;32(1):56-61. doi: 10.1016/j.sjopt.2018.02.017. Epub 2018 Mar 10.

34.

PD-L1 expression in medulloblastoma: an evaluation by subgroup.

Martin AM, Nirschl CJ, Polanczyk MJ, Bell WR, Nirschl TR, Harris-Bookman S, Phallen J, Hicks J, Martinez D, Ogurtsova A, Xu H, Sullivan LM, Meeker AK, Raabe EH, Cohen KJ, Eberhart CG, Burger PC, Santi M, Taube JM, Pardoll DM, Drake CG, Lim M.

Oncotarget. 2018 Apr 10;9(27):19177-19191. doi: 10.18632/oncotarget.24951. eCollection 2018 Apr 10.

35.

A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease.

Bell WR, Meeker AK, Rizzo A, Rajpara S, Rosenthal IM, Flores Bellver M, Aparicio Domingo S, Zhong X, Barber JR, Joshu CE, Canto-Soler MV, Eberhart CG, Heaphy CM.

Brain Pathol. 2019 Jan;29(1):45-52. doi: 10.1111/bpa.12618. Epub 2018 May 23.

PMID:
29668072
36.

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.

Schreck KC, Guajardo A, Lin DDM, Eberhart CG, Grossman SA.

J Natl Compr Canc Netw. 2018 Apr;16(4):343-347. doi: 10.6004/jnccn.2017.7052.

PMID:
29632053
37.

Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma.

Merk DJ, Ohli J, Merk ND, Thatikonda V, Morrissy S, Schoof M, Schmid SN, Harrison L, Filser S, Ahlfeld J, Erkek S, Raithatha K, Andreska T, Weißhaar M, Launspach M, Neumann JE, Shakarami M, Plenker D, Marra MA, Li Y, Mungall AJ, Moore RA, Ma Y, Jones SJM, Lutz B, Ertl-Wagner B, Rossi A, Wagener R, Siebert R, Jung A, Eberhart CG, Lach B, Sendtner M, Pfister SM, Taylor MD, Chavez L, Kool M, Schüller U.

Dev Cell. 2018 Mar 26;44(6):709-724.e6. doi: 10.1016/j.devcel.2018.02.012. Epub 2018 Mar 15.

38.

INSM1 Expression Is Frequent in Primary Central Nervous System Neoplasms but Not in the Adult Brain Parenchyma.

Ames HM, Rooper LM, Laterra JJ, Eberhart CG, Rodriguez FJ.

J Neuropathol Exp Neurol. 2018 May 1;77(5):374-382. doi: 10.1093/jnen/nly014.

39.

Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors.

Casaos J, Huq S, Lott T, Felder R, Choi J, Gorelick N, Peters M, Xia Y, Maxwell R, Zhao T, Ji C, Simon T, Sesen J, Scotland SJ, Kast RE, Rubens J, Raabe E, Eberhart CG, Jackson EM, Brem H, Tyler B, Skuli N.

Oncotarget. 2018 Jan 3;9(8):8054-8067. doi: 10.18632/oncotarget.23883. eCollection 2018 Jan 30.

40.

No BRAF V600E Mutation Identified in 28 Periocular Pyogenic Granuloma.

Li G, Adams E, Eshleman JR, Eberhart CG.

Ophthalmic Plast Reconstr Surg. 2018 Nov/Dec;34(6):525-527. doi: 10.1097/IOP.0000000000001075.

PMID:
29406329
41.

Hemophagocytic Lymphohistiocytosis in Adults with Intraocular Involvement: Clinicopathologic Features of 3 Cases.

Vizcaino MA, Eberhart CG, Rodriguez FJ.

Ocul Oncol Pathol. 2017 Dec;4(1):1-11. doi: 10.1159/000475551. Epub 2017 Jun 1.

42.

Identifying Corneal Infections in Formalin-Fixed Specimens Using Next Generation Sequencing.

Li Z, Breitwieser FP, Lu J, Jun AS, Asnaghi L, Salzberg SL, Eberhart CG.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):280-288. doi: 10.1167/iovs.17-21617.

43.

Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.

Jiang S, Rui Q, Wang Y, Heo HY, Zou T, Yu H, Zhang Y, Wang X, Du Y, Wen X, Chen F, Wang J, Eberhart CG, Zhou J, Wen Z.

Eur Radiol. 2018 May;28(5):2115-2123. doi: 10.1007/s00330-017-5182-4. Epub 2017 Dec 12.

44.

Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy.

Hu J, Dziumbla S, Lin J, Bibli SI, Zukunft S, de Mos J, Awwad K, Frömel T, Jungmann A, Devraj K, Cheng Z, Wang L, Fauser S, Eberhart CG, Sodhi A, Hammock BD, Liebner S, Müller OJ, Glaubitz C, Hammes HP, Popp R, Fleming I.

Nature. 2017 Dec 14;552(7684):248-252. doi: 10.1038/nature25013. Epub 2017 Dec 6.

45.

mTORC1-Mediated Inhibition of 4EBP1 Is Essential for Hedgehog Signaling-Driven Translation and Medulloblastoma.

Wu CC, Hou S, Orr BA, Kuo BR, Youn YH, Ong T, Roth F, Eberhart CG, Robinson GW, Solecki DJ, Taketo MM, Gilbertson RJ, Roussel MF, Han YG.

Dev Cell. 2017 Dec 18;43(6):673-688.e5. doi: 10.1016/j.devcel.2017.10.011. Epub 2017 Nov 2.

46.

HIF-1α- Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy.

Mangraviti A, Raghavan T, Volpin F, Skuli N, Gullotti D, Zhou J, Asnaghi L, Sankey E, Liu A, Wang Y, Lee DH, Gorelick N, Serra R, Peters M, Schriefer D, Delaspre F, Rodriguez FJ, Eberhart CG, Brem H, Olivi A, Tyler B.

Sci Rep. 2017 Nov 2;7(1):14978. doi: 10.1038/s41598-017-14990-w.

47.

An immunocompetent mouse model of human glioblastoma.

Semenkow S, Li S, Kahlert UD, Raabe EH, Xu J, Arnold A, Janowski M, Oh BC, Brandacher G, Bulte JWM, Eberhart CG, Walczak P.

Oncotarget. 2017 May 15;8(37):61072-61082. doi: 10.18632/oncotarget.17851. eCollection 2017 Sep 22.

48.

Strategies to enhance the distribution of nanotherapeutics in the brain.

Zhang C, Mastorakos P, Sobral M, Berry S, Song E, Nance E, Eberhart CG, Hanes J, Suk JS.

J Control Release. 2017 Dec 10;267:232-239. doi: 10.1016/j.jconrel.2017.07.028. Epub 2017 Jul 21.

49.

Melanoma subtypes demonstrate distinct PD-L1 expression profiles.

Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, Xu H, Ogurtsova A, Anders RA, Fischer AH, Kraft S, Gerstenblith MR, Thompson CL, Honda K, Cuda JD, Eberhart CG, Handa JT, Lipson EJ, Taube JM.

Lab Invest. 2017 Sep;97(9):1063-1071. doi: 10.1038/labinvest.2017.64. Epub 2017 Jul 24.

50.

Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.

Jiang S, Zou T, Eberhart CG, Villalobos MAV, Heo HY, Zhang Y, Wang Y, Wang X, Yu H, Du Y, van Zijl PCM, Wen Z, Zhou J.

Magn Reson Med. 2017 Sep;78(3):1100-1109. doi: 10.1002/mrm.26820. Epub 2017 Jul 16.

Supplemental Content

Loading ...
Support Center